Celtic Biotech is an early stage company developing novel therapeutic products for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients.
The Company aims to produce products that are safe, easily tolerated by patients, minimal to no side effects profile, reduced requirement for analgesics, toxic to tumour cells whilst sparing healthy cells. It is expected the products will be used as a monotherapy or in combination with other approved treatments.
Growth and aging of the human population are drivers of increasing cancer incidence and costs. Medical expenditures for cancer in the year 2020 are projected to reach at least $158 billion in the U.S. alone.
Celtic Biotech is focusing its research on solid tumours including non-small-cell lung cancer (NSCLC), breast, prostate, ovarian and cervical cancer as initial targets. These are some of the leading causes of cancer deaths worldwide, and there is a large unmet need in terms of effective therapies, particularly for late stage disease.
The Company's lead candidate CB24 (Crotoxin) has been observed to be highly toxic to various tumour cell types in pre-clinical studies and stabilised disease, partial responses, and even complete responses have been observed in a significant proportion of cancer patients in early clinical studies.
The Celtic Biotech team is dedicated to improving the health and quality of life of cancer patients world-wide.